BRPI0511754A - uso de um composto ou sais ou solvatos do mesmo - Google Patents

uso de um composto ou sais ou solvatos do mesmo

Info

Publication number
BRPI0511754A
BRPI0511754A BRPI0511754-2A BRPI0511754A BRPI0511754A BR PI0511754 A BRPI0511754 A BR PI0511754A BR PI0511754 A BRPI0511754 A BR PI0511754A BR PI0511754 A BRPI0511754 A BR PI0511754A
Authority
BR
Brazil
Prior art keywords
solvates
salts
compound
relates
quinazolinamines
Prior art date
Application number
BRPI0511754-2A
Other languages
English (en)
Inventor
Mark S Berger
Iman El-Hariry
Tona Morgan Gilmer
Arundathy Nirmalini Pandite
David Rusnak
Neil L Spector
Original Assignee
Smithkline Beechman Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beechman Cork Ltd filed Critical Smithkline Beechman Cork Ltd
Publication of BRPI0511754A publication Critical patent/BRPI0511754A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE UM COMPOSTO OU SAIS OU SOLVATOS DO MESMO A presente invenção diz respeito a um método de tratar o câncer em um mamífero pela administração de 4-quinazolinaminas e composições farmacêuticas que as contenham. Em particular, o método diz respeito a um método de tratar cânceres que são mediados pelas tirosina quinases EGER e/ou erbB2 pela administração de N-{3-cloro-4-¢(3-fluorobenzil)óxi!fenil}-6- ¢5 -({¢2-(metanossulfonil)etil!amino}metil)-2-furil!-4-quinazolinamina e sais e solvatos do mesmo.
BRPI0511754-2A 2004-06-03 2005-06-01 uso de um composto ou sais ou solvatos do mesmo BRPI0511754A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57682504P 2004-06-03 2004-06-03
US60679004P 2004-09-02 2004-09-02
PCT/US2005/019053 WO2005120504A2 (en) 2004-06-03 2005-06-01 Cancer treatment method

Publications (1)

Publication Number Publication Date
BRPI0511754A true BRPI0511754A (pt) 2008-01-02

Family

ID=35503647

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511754-2A BRPI0511754A (pt) 2004-06-03 2005-06-01 uso de um composto ou sais ou solvatos do mesmo

Country Status (14)

Country Link
US (1) US20100063074A1 (pt)
EP (1) EP1768963A4 (pt)
JP (1) JP2008501690A (pt)
KR (1) KR20070030240A (pt)
AU (1) AU2005251722B2 (pt)
BR (1) BRPI0511754A (pt)
CA (1) CA2569132A1 (pt)
IL (1) IL179359A0 (pt)
MA (1) MA28691B1 (pt)
MX (1) MXPA06013635A (pt)
NO (1) NO20066077L (pt)
NZ (1) NZ551622A (pt)
RU (1) RU2006142420A (pt)
WO (1) WO2005120504A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090042994A (ko) * 2006-08-22 2009-05-04 콘서트 파마슈티컬즈, 인크. 4-아미노퀴나졸린 유도체 및 이의 사용방법
WO2009137714A2 (en) 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010017387A2 (en) * 2008-08-06 2010-02-11 Teva Pharmaceutical Industries Ltd. Lapatinib intermediates
EP2158913A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
ES2673165T3 (es) 2012-03-23 2018-06-20 Array Biopharma, Inc. Dispersión sólida amorfa para la utilización en el tratamiento del cáncer cerebral
EA201992573A1 (ru) 2017-04-28 2020-04-06 Сиэтл Дженетикс, Инк. Лечение her2-положительных злокачественных новообразований

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
TWI307339B (en) * 2000-06-30 2009-03-11 Glaxo Group Ltd Quinazoline ditosylate salt comprounds
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
JP2004002210A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
JP2004002211A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
MXPA04010166A (es) * 2002-04-16 2005-02-03 Astrazeneca Ab Politerapia para el tratamiento de cancer.
WO2004000094A2 (en) * 2002-06-19 2003-12-31 Smithkline Beecham Corporation Predictive markers in cancer therapy
EP1534674A4 (en) * 2002-08-02 2007-11-28 Immunogen Inc CYTOTOXIC AGENTS CONTAINING NEW, EFFECTIVE TAXANES AND THEIR THERAPEUTIC USE
JP2004144680A (ja) * 2002-10-25 2004-05-20 Nanko Kyo 細胞増殖を制御する物質のスクリーニング方法、及びＳｐ１分子等をヌクレオリン（ｎｕｃｌｅｏｌｉｎ）分子から解離させる物質のスクリーニング方法

Also Published As

Publication number Publication date
NZ551622A (en) 2010-01-29
CA2569132A1 (en) 2005-12-22
RU2006142420A (ru) 2008-07-20
AU2005251722A1 (en) 2005-12-22
AU2005251722B2 (en) 2009-11-12
KR20070030240A (ko) 2007-03-15
EP1768963A2 (en) 2007-04-04
MXPA06013635A (es) 2007-02-28
WO2005120504A3 (en) 2006-02-23
IL179359A0 (en) 2007-03-08
JP2008501690A (ja) 2008-01-24
US20100063074A1 (en) 2010-03-11
WO2005120504A2 (en) 2005-12-22
NO20066077L (no) 2007-01-31
MA28691B1 (fr) 2007-06-01
EP1768963A4 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
MY169272A (en) Her2 antibody composition
CY1118846T1 (el) Τριαζολοπυριδαζινες ως ρυθμιστες της κινασης τυροσινης
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
CY1116191T1 (el) Παραγωγα πυριδαζινονης
CY1118498T1 (el) Παραγωγα πυριδαζινονης
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
BRPI0516968A (pt) composto, composição, e, método de tratamento de distúrbio hiperproliferativo
CY1116015T1 (el) Καινοφανεις ενωσεις και μεθοδοι για θεραπεια
ATE554087T1 (de) Neue kinaseinhibitoren
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
BRPI0518794A2 (pt) composto, composiÇço, mÉtodo de tratamento de distérbio hiperproliferativo, e, biblioteca combinatorial
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
EA200901611A1 (ru) Производные 2-оксо-3-бензил-бензоксазол-2-она и родственные соединения в качестве ингибиторов мет киназы для лечения опухолей
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA201001648A1 (ru) Производные пиридазинона
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
CY1108061T1 (el) Παραγωγα κιναζολινης ως src αναστολεις κινασης τυροσινης
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
CY1113698T1 (el) Παραγωγα πυριδαζινονης
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
EA201000618A1 (ru) 5-цианотиенопиридины для лечения опухолей

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.